BioCorRx (BICX) Gross Profit (2011 - 2026)

BioCorRx has disclosed Gross Profit across 16 years of filings, most recently posting $189355.0 for Q1 2026.

• Gross Profit for Q1 2026 came in at $189355.0, up 40.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $324254.0 (up 133.37% YoY), and the FY2024 annual result was $5998.0, down 88.72% from the prior year.
• Gross Profit came in at $189355.0 for Q1 2026 at BioCorRx, up from $134899.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $189355.0 in Q1 2026 to a low of $1953.0 in Q1 2024.
• The 5-year median for Gross Profit is $16130.0 (2022), against an average of $48499.0.
• Across the five-year window, Gross Profit slumped 93.85% in 2024 and surged 6807.27% in 2025, its largest moves.
• BioCorRx's Gross Profit stood at $74204.0 in 2022, then sank by 92.07% to $5885.0 in 2023, then slumped by 31.27% to $4045.0 in 2024, then surged by 3234.96% to $134899.0 in 2025, then surged by 40.37% to $189355.0 in 2026.
• The last three Gross Profit figures came in at $189355.0 (Q1 2026), $134899.0 (Q1 2025), and $4045.0 (Q2 2024), per Business Quant data.